Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Core Insights - Adverum Biotechnologies, Inc. will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 [1] - The chat will feature Laurent Fischer, MD, and Szilárd Kiss, MD, discussing the company's advancements in gene therapy for ocular diseases [1] Company Overview - Adverum Biotechnologies is a clinical-stage company focused on gene therapy aimed at preserving sight in prevalent ocular diseases [3] - The company is developing a novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), intended as a one-time intravitreal injection for patients with neovascular or wet age-related macular degeneration [3] - Adverum aims to transform the standard of care for ocular diseases by providing durable, single-administration therapies that reduce the need for frequent ocular injections [3]